{"id":6359,"date":"2021-03-24T20:37:25","date_gmt":"2021-03-25T00:37:25","guid":{"rendered":"https:\/\/edecmo.org\/?p=6359"},"modified":"2021-11-02T18:12:50","modified_gmt":"2021-11-02T22:12:50","slug":"72-should-we-all-switch-to-bivalirudin","status":"publish","type":"post","link":"https:\/\/edecmo.org\/72-should-we-all-switch-to-bivalirudin\/","title":{"rendered":"72: Should We All Switch To Bivalirudin?"},"content":{"rendered":"<!--powerpress_player--><div class=\"powerpress_player\" id=\"powerpress_player_7463\"><!--[if lt IE 9]><script>document.createElement('audio');<\/script><![endif]-->\n<audio class=\"wp-audio-shortcode\" id=\"audio-6359-1\" preload=\"none\" style=\"width: 100%;\" controls=\"controls\"><source type=\"audio\/mpeg\" src=\"https:\/\/media.blubrry.com\/edecmo\/traffic.libsyn.com\/secure\/edecmo\/EDECMO72.mp3?_=1\" \/><a href=\"https:\/\/media.blubrry.com\/edecmo\/traffic.libsyn.com\/secure\/edecmo\/EDECMO72.mp3\">https:\/\/media.blubrry.com\/edecmo\/traffic.libsyn.com\/secure\/edecmo\/EDECMO72.mp3<\/a><\/audio><\/div><p class=\"powerpress_links powerpress_links_mp3\" style=\"margin-bottom: 1px !important;\">Podcast: <a href=\"https:\/\/media.blubrry.com\/edecmo\/traffic.libsyn.com\/secure\/edecmo\/EDECMO72.mp3\" class=\"powerpress_link_pinw\" target=\"_blank\" title=\"Play in new window\" onclick=\"return powerpress_pinw('https:\/\/edecmo.org\/?powerpress_pinw=6359-podcast');\" rel=\"nofollow\">Play in new window<\/a> | <a href=\"https:\/\/media.blubrry.com\/edecmo\/traffic.libsyn.com\/secure\/edecmo\/EDECMO72.mp3\" class=\"powerpress_link_d\" title=\"Download\" rel=\"nofollow\" download=\"EDECMO72.mp3\">Download<\/a> (Duration: 29:39 &#8212; 24.3MB)<\/p><p class=\"powerpress_links powerpress_subscribe_links\">Subscribe: <a href=\"https:\/\/edecmo.org\/feed\/podcast\/\" class=\"powerpress_link_subscribe powerpress_link_subscribe_rss\" target=\"_blank\" title=\"Subscribe via RSS\" rel=\"nofollow\">RSS<\/a><\/p><p>Heparin has been the mainstay of anticoagulation for ECMO patients for years.\u00a0 In recent years, this has been challenged.\u00a0 Bivalirudin has b<img loading=\"lazy\" decoding=\"async\" class=\"wp-image-6360 alignleft\" src=\"https:\/\/edecmo.org\/wp-content\/uploads\/2021\/03\/media_15f641e_Rivosecchi_Ryan_Pittsburgh_2.jpg\" alt=\"\" width=\"158\" height=\"158\" srcset=\"https:\/\/edecmo.org\/wp-content\/uploads\/2021\/03\/media_15f641e_Rivosecchi_Ryan_Pittsburgh_2.jpg 400w, https:\/\/edecmo.org\/wp-content\/uploads\/2021\/03\/media_15f641e_Rivosecchi_Ryan_Pittsburgh_2-150x150.jpg 150w\" sizes=\"(max-width: 158px) 100vw, 158px\" \/>ecome a potential better anticoagulant.\u00a0 Troy Seelhammer in EDECMO episode 55 gave us some insight into this.\u00a0 This month Ryan Rivosecchi and his crew at UPitt have released their findings in Critical Care Medicine.\u00a0 This retrospective study suggests great improvement in major bleeding in patients who received Bivalirudin compare to Heparin (40.7% vs 11.7%, <em>p <\/em>&lt; 0.001).\u00a0 Listen to Ryan and Zack discuss anticoagulant use in ECMO patients in this month&#8217;s episode.<br \/>\n<img loading=\"lazy\" decoding=\"async\" class=\"wp-image-6361 alignright\" src=\"https:\/\/edecmo.org\/wp-content\/uploads\/2021\/03\/vial.jpg\" alt=\"\" width=\"118\" height=\"253\" \/><\/p>\n<p>Rivosecchi RM, Arakelians AR, Ryan J, Murray H, Padmanabhan R, Gomez H, Phillips D, Sciortino C, Arlia P, Freeman D, Sappington PL, Sanchez PG. Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin. Crit Care Med. 2021 Mar 15. doi: 10.1097\/CCM.0000000000004944. Epub ahead of print. PMID: 33711003.<\/p>\n<p>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Heparin has been the mainstay of anticoagulation for ECMO patients for years.\u00a0 In recent years, this has been challenged.\u00a0 Bivalirudin has b<br \/>\necome a potential better anticoagulant.\u00a0 Troy Seelhammer in EDECMO episode 55 gave us some insight into this.\u00a0 This month Ryan Rivosecchi and his crew at UPitt have released their findings in Critical Care Medicine.\u00a0 This retrospective study suggests great improvement in major bleeding in patients who received Bivalirudin compare to Heparin (40.7% vs 11.7%, p < 0.001).\u00a0 Listen to Ryan and Zack discuss anticoagulant use in ECMO patients in this month's episode.\n\n\nRivosecchi RM, Arakelians AR, Ryan J, Murray H, Padmanabhan R, Gomez H, Phillips D, Sciortino C, Arlia P, Freeman D, Sappington PL, Sanchez PG. Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin. Crit Care Med. 2021 Mar 15. doi: 10.1097\/CCM.0000000000004944. Epub ahead of print. PMID: 33711003.\n\n.\n<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"72: Should We All Switch To Bivalirudin?","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[4],"tags":[330,332,120,159,364,24,223],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p3JzC4-1Ez","_links":{"self":[{"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/posts\/6359"}],"collection":[{"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/comments?post=6359"}],"version-history":[{"count":1,"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/posts\/6359\/revisions"}],"predecessor-version":[{"id":6783,"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/posts\/6359\/revisions\/6783"}],"wp:attachment":[{"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/media?parent=6359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/categories?post=6359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/edecmo.org\/wp-json\/wp\/v2\/tags?post=6359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}